IP Library › Granted Patent US 7,342,106
Granted Patent B2
US 7,342,106 · App. 10/527,823 · Granted Mar 11, 2008

Human antihuman MCP-1 antibody and antibody fragment thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,342,106
App. No.
10/527,823
Granted
Mar 11, 2008
Kind
B2
Abstract

A substance effective for treating immunopathy where MCP-1 is involved is provided. scFv having a high affinity to human MCP-1 was obtained using phage antibody technique. Based on information of VH chain and VL chain obtained from said scFv, a human anti-human MCP-1 antibody and a human anti-human MCP-1 antibody fragment are obtained. Said antibody and antibody fragment are expected to be useful as a medicament for treating inflammation and immunopathy caused by MCP-1.

Claims (96)

1. An isolated DNA molecule coding for a single chain Fv (scFv) of a human anti-human MCP-1 antibody that binds to human MCP-1, said DNA molecule comprising a DNA coding for a VH chain of said human anti-human MCP-1 antibody combined with a DNA coding for a VL chain of said human anti-human MCP-1 antibody, wherein complementarity determining regions (CDR1 to CDR3) of said VH chain have the following amino acid sequences:

CRD1:

Ser Tyr Ala Ile Ser,

(SEQ ID NO: 3)

CDR2:

Gly Phe Asp Pro Glu Asp Gly

(SEQ ID NO: 4)

Glu Thr Ile Tyr Ala Gln Lys

Phe Gln Gly

and

CDR3:

Asp Leu Gly Gly Gly Asp Tyr

(SEQ ID NO: 5)

Tyr Tyr Gly Met Asp Val

and complementarity determining regions (CDR1 to CDR3) of said VL chain have the following amino acid sequences:

CDR1:

Arg Ser Ser Gln Ser Ile Asn

(SEQ ID NO: 8)

Thr Tyr Leu His,

CDR2:

Ala Ala Ser Thr Leu Gln Ser

(SEQ ID NO: 9)

and

CDR3:

Gln Gln Ser Phe Thr Thr Pro

(SEQ ID NO: 10)

Leu Thr.

2. An isolated DNA molecule coding for a single chain Fv (scFv) of a human anti-human MCP-1 antibody that binds to human MCP-1, said DNA molecule comprising a DNA coding for a VH chain of said human anti-human MCP-1 antibody combined with a DNA coding for a VL chain of said human anti-human MCP-1 antibody, wherein said VH chain has the amino acid sequence depicted in SEQ ID NO: 2 and said VL chain has the amino acid sequence depicted in SEQ ID NO: 7.

3. The isolated DNA molecule of claim 2 , wherein said VH chain consists of the amino acid sequence depicted in SEQ ID NO: 2 and said VL chain consists of the amino acid sequence depicted in SEQ ID NO: 7.

4. An isolated DNA molecule coding for a human anti-human MCP-1 antibody that binds to human MCP-1, said DNA molecule comprising a DNA coding for a VH chain of said human anti-human MCP-1 antibody combined with a DNA coding for a human antibody CH chain and a DNA coding for a VL chain of said human anti-human MCP-1 antibody combined with a DNA coding for a human antibody CL chain, wherein complementarity determining regions (CDR1 to CDR3) of said VH chain have the following amino acid sequences:

CRD1:

Ser Tyr Ala Ile Ser,

(SEQ ID NO: 3)

CDR2:

Gly Phe Asp Pro Glu Asp Gly

(SEQ ID NO: 4)

Glu Thr Ile Tyr Ala Gln Lys

Phe Gln Gly

and

CDR3:

Asp Leu Gly Gly Gly Asp Tyr

(SEQ ID NO: 5)

Tyr Tyr Gly Met Asp Val

and complementarity determining regions (CDR1 to CDR3) of said VL chain have the following amino acid sequences:

CRD1:

Arg Ser Ser Gln Ser Ile Asn

(SEQ ID NO: 8)

Thr Tyr Leu His,

CDR2:

Ala Ala Ser Thr Leu Gln Ser

(SEQ ID NO: 9)

and

CDR3:

Gln Gln Ser Phe Thr Thr Pro

(SEQ ID NO: 10)

Leu Thr.

5. An isolated DNA molecule coding for a human anti-human MCP-1 antibody that binds to human MCP-1, said DNA molecule consisting of a DNA coding for a VH chain of said human anti-human MCP-1 antibody combined with a DNA coding for a human antibody CH chain and a DNA coding for a VL chain of said human anti-human MCP-1 antibody combined with a DNA coding for a human antibody CL chain, wherein said VH chain has the amino acid sequence depicted in SEQ ID NO: 2 and said VL chain has the amino acid sequence depicted in SEQ ID NO: 7.

6. An isolated DNA molecule coding for a human anti-human MCP-1 antibody fragment that binds to human MCP-1, said DNA molecule consisting of a DNA coding for the VH chain of said human anti-human MCP-1 antibody combined with a DNA coding for a portion of a human antibody CH chain and a DNA coding for a VL chain of said human anti-human MCP-1 antibody combined with a DNA coding for a portion of a human antibody CL chain, wherein complementarity determining regions (CDR1 to CDR3) of said VH chain have the following amino acid sequences:

CRD1:

Ser Tyr Ala Ile Ser,

(SEQ ID NO: 3)

CDR2:

Gly Phe Asp Pro Glu Asp Gly

(SEQ ID NO: 4)

Glu Thr Ile Tyr Ala Gln Lys

Phe Gln Gly

and

CDR3:

Asp Leu Gly Gly Gly Asp Tyr

(SEQ ID NO: 5)

Tyr Tyr Gly Met Asp Val

and complementarity determining regions (CDR1 to CDR3) of said VL chain have the following amino acid sequences:

CDR1: Arg Ser Ser Gln Ser Ile Asn Thr Tyr Leu His (SEQ ID NO: 8),

CDR2: Ala Ala Ser Thr Leu Gln Ser (SEQ ID NO: 9) and

CDR3: Gln Gln Ser Phe Thr Thr Pro Leu Thr (SEQ ID NO: 10).

7. An isolated DNA molecule coding for a human anti-human MCP-1 antibody fragment that binds to human MCP-1, said DNA molecule consisting of a DNA coding for the VH chain of said human anti-human MCP-1 antibody combined with a DNA coding for a portion of a human antibody CH chain and a DNA coding for a VL chain of said human anti-human MCP-1 antibody combined with a DNA coding for a portion of a human antibody CL chain, wherein said VH chain has the amino acid sequence depicted in SEQ ID NO: 2 and said VL chain has the amino acid sequence depicted in SEQ ID NO: 7.

8. An isolated DNA molecule coding for a human anti-human MCP-1 antibody fragment that binds to human MCP-1, said DNA molecule consisting of the scFv coding DNA molecule of claim 1 combined with either a DNA coding for a portion of a human antibody CH chain or with a DNA coding for a portion of a human antibody CL chain, wherein complementarity determining regions (CDR1 to CDR3) of said VH chain have the following amino acid sequences;

CRD1:

Ser Tyr Ala Ile Ser,

(SEQ ID NO: 3)

CDR2:

Gly Phe Asp Pro Glu Asp Gly

(SEQ ID NO: 4)

Glu Thr Ile Tyr Ala Gln Lys

Phe Gln Gly

and

CDR3:

Asp Leu Gly Gly Gly Asp Tyr

(SEQ ID NO: 5)

Tyr Tyr Gly Met Asp Val

and complementarity determining regions (CDR1 to CDR3) of said VL chain have the following amino acid sequences:

CDR1: Arg Ser Ser Gln Ser Ile Asn Thr Tyr Leu His (SEQ ID NO: 8),

CDR2: Ala Ala Ser Thr Leu Gln Ser (SEQ ID NO: 9) and

CDR3: Gln Gln Ser Phe Thr Thr Pro Leu Thr (SEQ ID NO: 10).

9. The isolated DNA molecule coding for a human anti-human MCP-1 antibody fragment that binds to human MCP-1, said DNA molecule consisting of the scFv coding DNA molecule of claim 1 combined with either a DNA coding for a portion of a human antibody CH chain or with a DNA coding for a portion of a human antibody CL chain, wherein said VH chain has an amino acid sequence depicted in SEQ ID NO: 2 and said VL chain has the amino acid sequence depicted in SEQ ID NO: 7.

10. The isolated DNA molecule of claim 1 which consists of said DNA coding for a VH chain of said human anti-human MCP-1 antibody combined with said DNA coding for a VL chain of said human anti-human MCP-1 antibody.

Assignments (2)
CHANGE OF NAME Recorded Jan 16, 2013
From: JURIDICAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
To: THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 029636/0944 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2006
From: SUGIMURA, KAZUHISA; NAKASHIMA, TOSHIHIRO; NISHIHARA, TSUKASA
To: JUDICIAL FOUNDATION THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE
Reel/Frame 018672/0829 →